June 2016, Vol. 5, No. 5
Multivitamin Use During Chemotherapy May Reduce Risk of Peripheral Neuropathy
Multivitamin supplement use was associated with a reduction in chemotherapy-associated peripheral neuropathy in a subanalysis of the SWOG S0221 trial. Patients who were using multivitamins before chemotherapy had 40% less neuropathy, and those using them during or after treatment had a 23% reduced risk.
The results were reported at the American Association for Cancer Research Annual Meeting by Gary R. Zirpoli, PhD, a Postdoctoral Fellow at Roswell Park Cancer Institute, Buffalo, NY.
â€śWe didnâ€™t see any association with individual vitamin supplements, but we found that multivitamin users reported less chemotherapy-induced peripheral neuropathy (CIPN), compared to patients not using them,â€ť Dr Zirpoli said. â€śTo our knowledge, this has not been reported before.â€ť
Although vitamin supplements have been explored for their potentially protective effects, â€śpromising candidates have not panned out,â€ť he noted. â€śThere really seems to be no good data showing their benefit.â€ť
SWOG 0221 evaluated the benefit of weekly versus biweekly paclitaxel (plus doxorubicin/cyclophosphamide) in breast cancer patients at high risk for recurrence. Embedded within the trial design was a questionnaire about diet and other lifestyle factors.
Dr Zirpoliâ€™s study included 1225 participants who completed questionnaires before and at diagnosis, of whom 1068 also completed a 6-month follow-up questionnaire to capture supplement use during treatment.
Symptoms of CIPN were measured using the physician-assessed National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) and the self-reported Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) subscale. The subscale measures hand and foot numbness, hand and foot discomfort, joint and muscle pain, weakness, ringing in the ears, and trouble hearing, buttoning, feeling small objects, and walking. Answers of â€śquite a bitâ€ť and â€śvery muchâ€ť were grouped together to represent severe neuropathy. â€śSomewhatâ€ť was considered moderate, and â€śa little bitâ€ť was considered mild.
Women were classified as supplement users if they used a supplement at least once a week. The analyses were adjusted for age, body mass index, race, smoking status, physical activity level, alcohol intake, and treatment.
Reductions in CIPN with Multivitamin Use Before and During Treatment
As measured by the CTCAE, grade 3/4 CIPN was reported by 62% of patients who took multivitamins before diagnosis compared with 38% who did not; grades 0 to 2 were reported by 52% and 48%, respectively.
This translated into a reduction in CIPN of 40% (odds ratio [OR] = 0.60; 95% CI, 0.42-0.87), primarily among the severe group. There were numerical differences favoring vitamin C and vitamin E, but the effect was not statistically significant.
As measured by the FACT/GOG-Ntx, there was a 22% reduction for women taking a multivitamin before diagnosis (OR = 0.78; 95% CI, 0.61-1.00).
For supplement use during treatment, risk was reduced by 23% for multivitamin users, according to the FACT/GOG-Ntx survey. No significant reductions were observed on the CTCAE instrument.
â€śOur results indicate that the use of multivitamins, but not individual dietary supplements, during treatment may reduce CIPN symptoms, although these findings require replication in larger studies,â€ť Dr Zirpoli said.
â€śItâ€™s important for other studies to verify these results, because itâ€™s possible there is some other characteristic that helps explain why patients taking multivitamin supplements have less neuropathy,â€ť he added.
Dear Colleague, This issue of Personalized Medicine in Oncology (PMO) is a testament to how far weâ€™ve come in our understanding of, and novel approaches to, the treatment of cancer. Armed with knowledge of molecular biomarkers, genetic mutations, genomics, immunotherapeutics, and targeted therapies, we are better able to treat patients [ Read More ]
Immunotherapy with the programmed death 1 (PD-1) inhibitor pembrolizumab induced durable responses in a phase 2 clinical trial of a virus-related cancer. Among 26 patients with Merkel cell carcinoma (MCC) treated in the trial, 12 of 14 patients (86%) who responded to pembrolizumab have ongoing responses after a median follow-up [ Read More ]